Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL2854194 | 0.94 | GBA1 (0.52) | GBA1CCR3 | |
| SCHEMBL3699320 | 0.93 | GBA1 (0.50) | GBA1CCR3GRIN2BHTR1ASIGMAR1 | |
| Formic Acid SCHEMBL29099960 | 0.91 | GBA1 (0.49) | GBA1CCR3GRIN2BHTR1ASIGMAR1 | |
| SCHEMBL4865561 | 0.88 | GBA1 (0.48) | GBA1CCR3GRIN2BHTR1ASIGMAR1 | |
| SCHEMBL4865573 | 0.88 | GBA1 (0.48) | GBA1CCR3GRIN2BHTR1ASIGMAR1 | |
| SCHEMBL6399920 | 0.88 | GBA1 (0.53) | GBA1CCR3GRIN2BSIGMAR1DDB1 | |
| SCHEMBL6398813 | 0.86 | GBA1 (0.52) | GBA1CCR3GRIN2BSIGMAR1DDB1 | |
| SCHEMBL7306646 | 0.83 | GRIN2B (0.75) | CCR3GRIN2BPRMT3CARM1PRMT6 | |
| SCHEMBL2027845 | 0.82 | GBA1 (0.71) | GBA1CCR3GRIN2BSIGMAR1PRMT3 | |
| SCHEMBL674276 | 0.82 | GBA1 (0.71) | GBA1CCR3GRIN2BSIGMAR1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865889-A | Synthesis method of benzisoquinoline compound | 山东省药学科学院 | 2024-04-12 | — | — | CN | claimed |
| CN-117865889-B | Benzisoquinolines method for synthesizing compound | 山东省药学科学院 | 2025-04-29 | — | — | CN | disclosed |
| EP-3962915-B1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2024-09-04 | — | — | EP | disclosed |
| CN-118043471-A | Process for the production of (1 r,4 r) -4-substituted cyclohexane-1-amines | 吉瑞工厂 | 2024-05-14 | — | — | CN | disclosed |
| CN-117865889-A | Synthesis method of benzisoquinoline compound | 山东省药学科学院 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2022-06-16 | — | — | US | disclosed |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2022-06-16 | — | — | US | disclosed |
| EP-3962915-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2022-03-09 | — | — | EP | disclosed |
| CN-108474885-B | Near-infrared absorbing composition for solid-state imaging element, filter, and solid-state imaging element | 东洋油墨SC控股株式会社 | 2021-04-13 | — | — | CN | disclosed |
| US-5712281-A | Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines | FMC CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0780369-A1 | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol derivatives as pharmaceutical agents | Grünenthal GmbH (DE) | 1997-06-25 | — | — | EP | disclosed |
| US-5618980-A | DEHYDROGENATING N-CYCLOHEXYLIDENEAMINO COMPOUND IN PRESENCE OF HYDROGEN TRANSFER CATALYST AND HYDROGEN ACCEPTOR AND ALKALI OR ALKALINE EARTH METAL COMPOUND COCATALYST | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-04-08 | — | — | US | disclosed |
| EP-0588060-B1 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0753505-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5536725-A | Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines | FMC CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| US-5536878-A | HYDROGEN ACCEPTOR | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5382690-A | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-01-17 | — | — | US | disclosed |
| EP-0588060-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-03-23 | — | — | EP | disclosed |
| US-4346101-A | NON-SEDATING | THE UPJOHN COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | NR1I2, NR1H2, NR1H4 | GBA1 877/4885CCR3 514/4885GRIN2B 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.